Regeneron Pharmaceuticals (REGN) Capital Expenditures (2009 - 2026)

Regeneron Pharmaceuticals' Capital Expenditures history runs 18 years deep, the most recent figure standing at $230.6 million for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 0.57% year-over-year to $230.6 million in Q1 2026; TTM through Mar 2026 was $899.7 million, a 5.69% increase from a year earlier, with the FY2025 full-year figure at $898.4 million, up 18.85% from the prior year.
• Capital Expenditures fell to $230.6 million in Q1 2026 per REGN's latest filing, from $248.7 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $470.9 million in Q3 2025 and bottomed at -$102.8 million in Q2 2023.
• The 5-year median for Capital Expenditures is $178.2 million (2023), against an average of $187.9 million.
• Across the five-year window, Capital Expenditures soared 174.95% in 2023 and sank 385.31% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $152.2 million in 2022, then surged by 65.18% to $251.4 million in 2023, then dropped by 20.6% to $199.6 million in 2024, then rose by 24.6% to $248.7 million in 2025, then declined by 7.28% to $230.6 million in 2026.
• Per Business Quant, the three latest REGN Capital Expenditures figures stand at $230.6 million (Q1 2026), $248.7 million (Q4 2025), and $470.9 million (Q3 2025).